Physician profile
Howard A Aks
NPI 1932190105
$518.29
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $51.10.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $182.44 | 2019 | |
| Daiichi Sankyo INC. | $46.51 | 2019 | |
| Nevro Corp. | $41.41 | 2019 | |
| Pfizer INC. | $39.48 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $33.66 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.36 | 2019 | |
| Medtronic USA, INC. | $25.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $24.10 | 2019 | |
| Assertio Therapeutics, INC. | $19.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.03 | 2020 | |
| Collegium Pharmaceutical, INC. | $16.95 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.78 | 2019 | |
| Sentynl Therapeutics, INC. | $14.00 | 2019 | |
| Boston Scientific Corporation | $13.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Aks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.